13 Best IPO Stocks to Buy According to Wall Street Analysts

Page 12 of 12

1. Lexeo Therapeutics Inc. (NASDAQ:LXEO)

Number of Hedge Fund Holders: 20

Average Upside Potential as of August 15: 343.46%

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 7, the US FDA granted Breakthrough Therapy designation to Lexeo Therapeutics for its investigational drug, LX2006, which is a gene therapy for Friedreich ataxia/FA.

The designation was based on interim clinical data from two ongoing trials—the Lexeo-sponsored SUNRISE-FA Phase 1/2 trial and the Weill Cornell Medicine investigator-initiated Phase 1A trial. To date, 17 participants have been treated across both studies. The interim data showed that LX2006 was associated with clinically meaningful improvements in cardiac biomarkers and cardiac and neurologic functional measures.

In all participants with available cardiac biopsies, an increase in frataxin expression was observed three months after treatment. This is particularly significant as cardiomyopathy is the leading cause of death in FA, with cardiac dysfunction accounting for the cause of death in approximately two-thirds of patients. The company expects to begin a registrational study by early 2026 and is currently enrolling patients in a natural history study, CLARITY-FA, to serve as an external control arm.

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases with high unmet need in the US.

While we acknowledge the potential of LXEO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LXEO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 12 of 12